Combined approach with biologics and surgery for enterocutaneous fistulas in Crohn's disease

Inflammatory Bowel Diseases

Volumn 17, Issue 2, 2011, Pages 671-673

  Fries, Walter ^a   La Malfa, Giuseppe ^a   Costantino, Giuseppe ^a   Repici, Alessandro ^b   Mazziotti, Silvio ^a   Navarra, Giuseppe ^b  

^a UNIVERSITY OF MESSINA   (Italy)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIBIOTIC AGENT; INFLIXIMAB; MESALAZINE; METHYLPREDNISOLONE; METRONIDAZOLE; STEROID;

ABSCESS; ADULT; ANASTOMOSIS LEAKAGE; CASE REPORT; COLON ANASTOMOSIS; COLON RESECTION; COLOSTOMY; COMPUTER ASSISTED TOMOGRAPHY; CROHN DISEASE; ENDOSCOPY; ENTEROCUTANEOUS FISTULA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; ILEOSTOMY; LETTER; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL EXAMINATION; PRIORITY JOURNAL; TRANSVERSE COLON;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; COMBINED MODALITY THERAPY; CROHN DISEASE; CUTANEOUS FISTULA; FEMALE; HUMANS; INTESTINAL FISTULA; MALE; MIDDLE AGED; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 78651292315     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21289     Document Type: Letter

References (10)

1. Poritz LS, Rowe WA, Koltun WA,. Remicade does not abolish the need for surgery in fistulizing Crohn's disease. Dis Colon Rectum. 2002; 45: 771-775.
2. Miehsler W, Reinisch W, Kazemi-Shirazi L, et al. Infliximab: lack of efficacy on perforating complications in Crohn's disease. Inflamm Bowel Dis. 2004; 10: 36-40.
3. Taxonera C, Schwartz DA, García-Olmo D,. Emerging treatments for complex perianal fistula in Crohn's disease. World J Gastroenterol. 2009; 15: 4263-4272.
4. Subramanian V, Pollok RC, Kang JY, et al. Systematic review of postoperative complications in patients with inflammatory bowel disease treated with immunomodulators. Br J Surg. 2006; 93: 793-799.
5. Marchal L, D'Haens G, Van Assche G, et al. The risk of post-operative complications associated with infliximab therapy for Crohn's disease: a controlled cohort study. Aliment Pharmacol Ther. 2004; 19: 749-754.
6. Tay GS, Binion DG, Eastwood D, et al. Multivariate analysis suggests improved perioperative outcome in Crohn's disease patients receiving immunomodulator therapy after segmental resection and/or strictureplasty. Surgery. 2003; 134: 565-572.
7. Colombel JF, Loftus EV Jr, Tremaine WJ, et al. Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy. Am J Gastroenterol. 2004; 99: 878-883.
8. Appau KA, Fazio VW, Shen B, et al. Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn's patients. J Gastrointest Surg. 2008; 12: 1738-1744.
9. Kunitake H, Hodin R, Shellito PC, et al. Perioperative treatment with infliximab in patients with Crohn's disease and ulcerative colitis is not associated with an increased rate of postoperative complications. J Gastrointest Surg. 2008; 12: 1730-1736.
10. Ferrante M, D'Hoore A, Vermeire S, et al. Corticosteroids but not infliximab increase short-term postoperative infectious complications in patients with ulcerative colitis. Inflamm Bowel Dis. 2009; 15: 1062-1017.